Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia

Overview

Journal Kidney Dis (Basel)

Specialty Nephrology

Date 2023 Feb 9

PMID 36756084

Authors

Jing Li

Volker H Haase

Chuan-Ming Hao

Affiliations

Soon will be listed here.

Abstract

Background: Anemia is a common complication of chronic kidney disease. The hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a new class of oral drugs for the treatment of renal anemia.

Summary: Clinical trials have consistently shown that HIF-PHIs can effectively increase hemoglobin in both the dialysis population and the nondialysis population. The effects of HIF-PHIs in treating renal anemia include promoting endogenous erythropoietin production and facilitating iron mobilization. Several studies suggest that the erythropoiesis effect of roxadustat is less affected by inflammation. Careful monitoring of thromboembolic events and tumor before and during HIF-PHI treatment is necessary.

Key Messages: HIF-PHIs are effective in correcting renal anemia. The long-term safety of HIF-PHIs needs to be further studied.

Citing Articles

Changes in Retinal Nerve Fiber Layer Thickness in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.

Xu Y, Shi P, Liu X, Jiang Z, Chen Y, Liu J Clin Respir J. 2025; 19(3):e70065.

PMID: 40035189 PMC: 11876992. DOI: 10.1111/crj.70065.

Anemia in diabetes mellitus: Pathogenetic aspects and the value of early erythropoietin therapy.

Antoniadou C, Gavriilidis E, Ritis K, Tsilingiris D Metabol Open. 2025; 25:100344.

PMID: 39886103 PMC: 11780985. DOI: 10.1016/j.metop.2024.100344.

Expression and Regulation of Hypoxia-Inducible Factor Signalling in Acute Lung Inflammation.

Lotsios N, Keskinidou C, Karagiannis S, Papavassiliou K, Papavassiliou A, Kotanidou A Cells. 2025; 14(1.

PMID: 39791730 PMC: 11719729. DOI: 10.3390/cells14010029.

Roxadustat Efficacy and Safety in Patients Receiving Peritoneal Dialysis: Pooled Analysis of Four Phase 3 Studies.

Fliser D, Bhandari S, Ortiz A, Santos V, Khalife N, Jiletcovici A J Clin Med. 2024; 13(22).

PMID: 39597872 PMC: 11595076. DOI: 10.3390/jcm13226729.

Recent Insights into Roles of Hypoxia-Inducible Factors in Retinal Diseases.

Lee D, Tomita Y, Miwa Y, Kunimi H, Nakai A, Shoda C Int J Mol Sci. 2024; 25(18).

PMID: 39337623 PMC: 11432567. DOI: 10.3390/ijms251810140.

References

Semenza G . VHL and p53: tumor suppressors team up to prevent cancer. Mol Cell. 2006; 22(4):437-9. DOI: 10.1016/j.molcel.2006.05.001. View

Rolfs A, Kvietikova I, Gassmann M, Wenger R . Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem. 1997; 272(32):20055-62. DOI: 10.1074/jbc.272.32.20055. View

Rossert J, Gassmann-Mayer C, Frei D, McClellan W . Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant. 2007; 22(3):794-800. DOI: 10.1093/ndt/gfl716. View

Barratt J, Sulowicz W, Schomig M, Esposito C, Reusch M, Young J . Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. Adv Ther. 2021; 38(10):5345-5360. PMC: 8478753. DOI: 10.1007/s12325-021-01903-7. View

Xu B, Liu S, Li Y, Zhao L, Song X, Chen T . Roxadustat in the treatment of a hemodialysis patient with anti-erythropoietin antibody-mediated pure red cell aplasia. Clin Kidney J. 2021; 14(11):2444-2445. PMC: 8573001. DOI: 10.1093/ckj/sfab134. View

Akizawa T, Nangaku M, Yamaguchi T, Arai M, Koretomo R, Matsui A . A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial. Am J Nephrol. 2019; 49(2):165-174. PMC: 6481254. DOI: 10.1159/000496929. View

Haase V . HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism. Hemodial Int. 2017; 21 Suppl 1:S110-S124. PMC: 5526677. DOI: 10.1111/hdi.12567. View

Hara K, Takahashi N, Wakamatsu A, Caltabiano S . Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet. 2015; 30(6):410-8. DOI: 10.1016/j.dmpk.2015.08.004. View

Bradbury B, Critchlow C, Weir M, Stewart R, Krishnan M, Hakim R . Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant. 2008; 24(3):919-25. DOI: 10.1093/ndt/gfn543. View

10.

Coyne D, Singh A, Lopes R, Bailey C, DiMino T, Huang C . Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Clin J Am Soc Nephrol. 2022; 17(9):1325-1336. PMC: 9625096. DOI: 10.2215/CJN.00550122. View

11.

Nangaku M, Kondo K, Kokado Y, Ueta K, Kaneko G, Tandai T . Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD. J Am Soc Nephrol. 2021; 32(7):1779-1790. PMC: 8425651. DOI: 10.1681/ASN.2020091311. View

12.

Akizawa T, Nangaku M, Yamaguchi T, Koretomo R, Maeda K, Miyazawa Y . A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study. Kidney Dis (Basel). 2021; 7(6):494-502. PMC: 8613566. DOI: 10.1159/000517053. View

13.

Akizawa T, Otsuka T, Reusch M, Ueno M . Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study. Ther Apher Dial. 2019; 24(2):115-125. PMC: 7079122. DOI: 10.1111/1744-9987.12888. View

14.

Taylor M, Qu A, Anderson E, Matsubara T, Martin A, Gonzalez F . Hypoxia-inducible factor-2α mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. Gastroenterology. 2011; 140(7):2044-55. PMC: 3109109. DOI: 10.1053/j.gastro.2011.03.007. View

15.

Provenzano R, Szczech L, Leong R, Saikali K, Zhong M, Lee T . Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials. Clin J Am Soc Nephrol. 2021; 16(8):1190-1200. PMC: 8455050. DOI: 10.2215/CJN.16191020. View

16.

Batchelor E, Kapitsinou P, Pergola P, Kovesdy C, Jalal D . Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. J Am Soc Nephrol. 2020; 31(3):456-468. PMC: 7062209. DOI: 10.1681/ASN.2019020213. View

17.

Ang S, Chen H, Hirota K, Gordeuk V, Jelinek J, Guan Y . Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002; 32(4):614-21. DOI: 10.1038/ng1019. View

18.

Chertow G, Pergola P, Farag Y, Agarwal R, Arnold S, Bako G . Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021; 384(17):1589-1600. DOI: 10.1056/NEJMoa2035938. View

19.

Fishbane S, Frei G, Maesaka J . Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995; 26(1):41-6. DOI: 10.1016/0272-6386(95)90151-5. View

20.

Akizawa T, Iwasaki M, Otsuka T, Yamaguchi Y, Reusch M . Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD. Kidney Int Rep. 2021; 6(7):1810-1828. PMC: 8258605. DOI: 10.1016/j.ekir.2021.04.003. View